Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Glioblastomas are heterogeneous and invariably lethal tumours. They are characterized by
genetic and epigenetic variations among tumour cells, which makes the development of …

Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …

Abstract Purpose: Combination PD-1 and CTLA-4 inhibitor therapy has dramatically
improved the survival of patients with advanced melanoma but is also associated with …

There is a critical need to improve our understanding of the pathogenesis of melanoma
brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and …

Purpose Broadening trial eligibility to improve accrual and access and to better reflect
intended-to-treat populations has been recognized as a priority. Historically, patients with …

Methods| The institutional review board of Dana-Farber Cancer Institute approved the
project and informed consent was waived. We identified 480 patients with newly diagnosed …

Brain tumors remain one of the most difficult tumors to treat and, depending on the
diagnosis, have a poor prognosis. Of brain tumors, glioblastoma (GBM) is the most common …

Inhibition of immune checkpoints programmed death 1 (PD-1) and cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) on T cells results in durable antitumor activity in melanoma …